
Last updated: 2026-09-10 21:03:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
First Tracks Biotherapeutics, Inc. (TRAX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $37.96, with a market capitalization of $1.49B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.72 to $49.91. This page covers its latest market performance, valuation, price trends and company information.
$1.49B | |
$39.35 | |
$49.91 | |
$14.72 | |
$39.57 | |
300.23K | |
767.43K | |
-- | |
$49.91 | |
$14.72 | |
-- | |
-- |
First Tracks Biotherapeutics, Inc. (TRAX) is trading at $37.98 in after-hours trading as of 2026-09-10 19:59:11, down 4.03% ($1.59) from the regular-session close of $39.57.
After-hours trading shows how investors are pricing TRAX after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, First Tracks Biotherapeutics, Inc. (TRAX) moved from $41.84 to $37.96, representing a decline of 9.26% ($3.88).
The stock traded between $37.51 and $47.98 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 686.07 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 66.1%
TRAX is currently trading at $37.96, placing it 66.1% of the way from its 52-week low of $14.72 to its 52-week high of $49.91. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
Eligible investors can buy real shares of First Tracks Biotherapeutics, Inc. (TRAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.